Search results
Showing 211 to 225 of 436 results for cardiovascular disease
What is the effectivness of statin treatment in older people?
Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification
MR-proADM test for use with clinical deterioration scores in cases of suspected infection (MIB195)
NICE has developed a medtech innovation briefing (MIB) on the MR-proADM test for use with clinical deterioration scores in cases of suspected infection .
Alitretinoin for the treatment of severe chronic hand eczema (TA177)
Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.
monitoring treatment and blood pressure targets for people without cardiovascular disease. Full details of the evidence and the...
the rationale and impact section on blood pressure targets for people with cardiovascular disease. Full details of the evidence and the...
Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)
Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)
Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.
the rationale and impact section on blood pressure targets for people with cardiovascular disease. Full details of the evidence and the...
Intrabeam radiotherapy for treating early breast cancer Cardiovascular conditions (heart disease and stroke) How do I...
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.
diabetes. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid...